OakChart

Vera Therapeutics Inc

VERAHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

30.48+0.45 (1.50%)
2026-11-12 00:33 CET
Market cap
2,171.13 USD m
Revenue, TTM
10.28 USD m
Net income, TTM
-415.31 USD m
Free cash flow, TTM
-376.05 USD m
EPS diluted, TTM
-5.91
P/E
-
Compare

Price

VERA against its 20, 50 and 200-day averages
2050200beat
30.0035.0040.0045.005.2M10.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VERAclose 30.4820-day 29.9250-day 31.38200-day 36.3130.4852w low

45.6% under the 52-week high of 56.05 on 24 Dec 2025. 52-week low 26.38 on 14 Oct 2026. Last 15 sessions, 19.4% high to low

Volume 0.83× normal · the line is the 50-bar volume average

Profile

VERA
52-week range, 14% of the way up
26.3856.05

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

IndexRUT
Employees249
IPOMay 14, 2021
Beta1.19
ATR, 14d1.73
Rel volume0.83
Short float20.68%
Insider own18.81%
Inst own100.61%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.20B
Enterprise Value1.90B
Income-415.31M
Sales10.28M
Book/sh4.61
Cash/sh5.31
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees249
IPOMay 14, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S214.36
P/B6.61
P/C5.74
P/FCF-
EV/EBITDA-
EV/Sales184.34
Quick Ratio7.31
Current Ratio7.44
Debt/Eq0.23
LT Debt/Eq0.23
Option/ShortYes / Yes

Earnings

EPS (ttm)-5.91
EPS next Y-3.73
EPS next Q-1.35
EPS this Y-27.59%
EPS next Y37.28%
EPS next 5Y53.13%
EPS past 3/5Y-11.65% -13.19%
Sales past 3/5Y- -
EPS Y/Y TTM-48.21%
Sales Y/Y TTM-
EPS Q/Q-3.32%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.19.65% 199.70%

Ownership

Insider Own18.81%
Insider Trans-0.88%
Inst Own100.61%
Inst Trans7.74%
ROA-84.48%
ROE-113.46%
ROIC-101.64%
Gross Margin56.58%
Oper. Margin-4160.07%
Profit Margin-4041.19%
SMA201.87%
SMA50-2.85%
SMA200-16.05%
Trades-

Technical

Shs Outstand72.29M
Shs Float58.70M
Short Float20.68%
Short Ratio5.88
Short Interest12.14M
52W High56.05 -45.62%
52W Low26.38 15.56%
Volatility6.59% 5.93%
ATR (14)1.73
RSI (14)50.46
Beta1.19
Rel Volume0.83
Avg Volume2.07M
Volume1,709,966

Performance

Perf Week-4.66%
Perf Month13.77%
Perf Quarter5.50%
Perf Half Y-22.15%
Perf YTD-39.81%
Perf Year2.59%
Perf 3Y151.07%
Perf 5Y36.93%
Perf 10Y-
Recom1.29
Target Price71.93
Prev Close30.03
Price30.48
Change %1.50%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Oct 12, 2026InitiatedLLeerink PartnersMarket Perform$34+11.5%
Mar 11, 2026UpgradeWWolfe ResearchPeer Perform → Outperform$88+188.7%
Oct 16, 2025InitiatedBBofA SecuritiesBuy$48+57.5%
Aug 04, 2025DowngradeWWolfe ResearchOutperform → Peer Perform
May 05, 2025ResumedHH.C. WainwrightBuy$75+146.1%
Feb 04, 2025InitiatedWWolfe ResearchOutperform$49+60.8%
Jan 28, 2025InitiatedGGoldmanBuy$58+90.3%
Nov 21, 2024InitiatedWWells FargoOverweight$70+129.7%
Oct 16, 2024InitiatedBScotiabankSector Outperform
Jan 25, 2024InitiatedOOppenheimerOutperform$26-14.7%

Peers

Mkt cap
TickerCompanyMkt cap
TVTXTravere Therapeutics Inc5.00B
VRTXVertex Pharmaceuticals Inc138.69B
JBIOJade Biosciences Inc1.05B
CLYMClimb Bio Inc719.55M
AUPHAurinia Pharmaceuticals Inc2.17B
MAZEMaze Therapeutics Inc2.01B
NVSNovartis AG ADR293.47B
ZBIOZenas Biopharma Inc1.95B
IMVTImmunovant Inc7.67B
ARGXArgen X SE ADR61.48B

Insider trading

latest 14 of 40
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Fordyce MarshallPRESIDENT AND CEOSep 15 '26Option Exercise2.9018,50053,591253,744Sep 17 04:28 PM
Fordyce MarshallPRESIDENT AND CEOSep 15 '26Sale37.0018,500684,500235,244Sep 17 04:28 PM
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRSep 11 '26Option Exercise3.945,00019,69880,754Sep 14 04:28 PM
Fordyce MarshallPRESIDENT AND CEOSep 02 '26Option Exercise2.9018,50053,591253,744Sep 04 04:15 PM
Fordyce MarshallPRESIDENT AND CEOSep 02 '26Sale35.1218,500649,642235,244Sep 04 04:15 PM
MARSHALL FORDYCEDirectorSep 02 '26Proposed Sale34.2364,7502,216,392Sep 02 04:32 PM
Fordyce MarshallPRESIDENT AND CEOJul 07 '26Sale42.3046,2501,956,187151,994Jul 09 04:45 PM
Fordyce MarshallPRESIDENT AND CEOJun 23 '26Sale37.9318,500701,769198,244Jun 24 04:55 PM
MARSHALL FORDYCEDirectorJun 23 '26Proposed Sale38.4374,0002,843,820Jun 23 04:29 PM
Fordyce MarshallPRESIDENT AND CEOMay 12 '26Sale36.7418,500679,747216,744May 13 04:26 PM
MARSHALL FORDYCEDirectorMay 12 '26Proposed Sale36.6118,500677,285May 12 04:33 PM
Fordyce MarshallPRESIDENT AND CEOApr 14 '26Sale44.0522,9511,011,051235,244Apr 15 04:57 PM
MARSHALL FORDYCEDirectorApr 14 '26Proposed Sale43.7122,9511,003,188Apr 14 04:33 PM
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRMar 13 '26Option Exercise3.9410,00039,39675,754Mar 16 06:52 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-1.300-1.618-1.30010.253.4212
2026Q22026-08-10-1.520-1.576-1.5240.000.0011
2026Q12026-05-07-1.690-1.328-1.6930.000.0010
2025Q42026-02-26-1.390-1.325-1.3950.000.0012
2025Q32025-11-05-1.260-1.162-1.2580.000.0012
2025Q22025-08-05-1.200-0.822-1.2000.000.0012
2025Q12025-05-06-0.810-0.741-0.8120.000.0011
2024Q42025-02-26-0.720-0.812-0.7190.000.0012
2024Q32024-11-07-0.850-0.638-0.8490.000.0010
2024Q22024-08-08-0.620-0.560-0.6160.000.008
2024Q12024-05-09-0.560-0.530-0.5570.000.006
2023Q42024-03-20-0.546-0.505-0.5770.000.0011
2023Q32023-11-09-0.450-0.519-0.4530.000.008
2023Q22023-08-10-0.460-0.653-0.4550.000.007
2023Q12023-05-11-0.800-0.569-0.7980.000.006
2022Q42023-03-28-1.167-0.865-1.1670.000.007

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-90.665--2.510--
2021FY-2.430-5.787-1.5330.000.00
2022FY-3.350-2.934-3.3520.000.00
2023FY-2.250-2.182-2.2480.000.00
2024FY-2.750-2.866-2.7500.000.00
2025FY-4.660-4.584-4.6610.000.00
2026FY--5.946--29.55
2027FY--3.729--253.52
2028FY--0.480--609.22
2029FY-2.822--1,031
2030FY-5.221--1,392

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-09118121.0310.9532.20
2026Q4S2026-11-06118121.0410.9532.20
2026Q4S2026-11-05103216.928.6921.80
2026Q4S2026-10-29103216.928.6921.80
2026Q4S2026-10-25113218.558.6934.90
2026Q4S2026-10-16114418.558.6934.90
2026Q4S2026-10-09113517.798.6934.90
2026Q4S2026-10-07103518.8010.9534.90
2026Q4S2026-09-19102517.9010.9534.90
2026Q4S2026-09-17102617.9010.9534.90
2026Q4S2026-09-07102717.9010.9534.90
2026Q4S2026-09-03102717.9111.0034.90
2026Q4S2026-08-28101717.799.8634.90
2026Q4S2026-08-25101718.729.8634.90

Estimate history

EPS, annual-3.46-2.51-1.533-3.352-2.248-2.75-4.664-5.9111
Period2019202020212022202320242025TTM
EPS, quarterly-0.849-0.719-0.812-1.2-1.258-1.395-1.693-1.524-1.299
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000010.28
Period2019202020212022202320242025TTM
Sales, quarterly0000000010.277
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual3.73221.27821.27827.80144.45263.5671.26772.288
Period2019202020212022202320242025MRQ
Shares, quarterly55.02663.5663.77463.82463.89571.26771.7371.95672.288
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue10.280.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A4.460.472.17-1.86-0.850.180.250.51
Gross Profit5.82-0.47-2.171.860.85-0.18-0.25-0.51
Selling, General and Administrative Excl. Other433.35315.00165.00103.8791.7534.0847.8111.28
Research and Development245.82214.79126.0782.3169.8422.3143.926.88
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-427.53-315.47-167.17-102.01-90.90-34.26-48.06-11.78
Interest Expense7.457.537.633.790.990.020.170.05
Unusual Expense0.000.000.000.050.811.045.190.27
Net Income Before Taxes-415.31-299.61-152.15-95.99-89.06-32.61-53.41-11.85
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-415.31-299.62-152.15-95.99-89.06-32.61-53.41-11.85
Net Income From Continuing Operations-415.31-299.62-152.15-95.99-89.06-32.61-53.41-11.85
Net Income-415.31-299.62-152.15-95.99-89.06-32.61-53.41-11.85
EPS (Recurring)-5.76-4.66-2.75-2.25-3.33-1.50-2.34-3.41
EPS (Basic, Before Extraordinaries)-5.91-4.66-2.75-2.25-3.35-1.53-2.51-3.46
EPS (Diluted)-5.91-4.66-2.75-2.25-3.35-1.53-2.51-3.46
EBITDA-425.94-315.00-165.00-103.87-91.75-34.08-47.81-11.28
Non-Operating Income (Expense)19.6723.3922.659.863.652.710.010.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense46.1329.9616.439.087.022.200.000.23
Price To Sales Ratio226.62-------
Gross Margin56.58-------
Operating Margin-4,160.07-------
Net Margin-4,041.19-------
Shares Outstanding72.2971.2763.5644.4527.8021.2821.283.73
Market Capitalization2,171.132,171.132,677.93683.38535.17568.54538.32-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue10.280.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A3.820.250.260.140.560.560.540.60
Gross Profit6.46-0.25-0.26-0.14-0.56-0.56-0.54-0.60
Selling, General and Administrative Excl. Other102.16112.24124.8894.0783.3779.5856.6548.31
Research and Development40.8359.9585.8759.1756.3458.0841.1933.29
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-95.70-112.49-125.13-94.21-83.93-80.14-57.19-48.91
Interest Expense1.871.851.821.901.961.871.791.87
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-93.71-109.47-121.03-91.10-80.29-76.53-51.69-43.42
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-93.71-109.47-121.03-91.10-80.29-76.53-51.69-43.42
Net Income From Continuing Operations-93.71-109.47-121.03-91.10-80.29-76.53-51.69-43.42
Net Income-93.71-109.47-121.03-91.10-80.29-76.53-51.69-43.42
EPS (Recurring)-1.30-1.52-1.69-1.39-1.26-1.20-0.81-0.72
EPS (Basic, Before Extraordinaries)-1.30-1.52-1.69-1.39-1.26-1.20-0.81-0.72
EPS (Diluted)-1.30-1.52-1.69-1.39-1.26-1.20-0.81-0.72
EBITDA-94.75-112.24-124.88-94.07-83.37-79.58-56.65-48.31
Non-Operating Income (Expense)3.864.875.925.015.605.487.297.36
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.7715.1513.213.009.749.477.744.91
Price To Sales Ratio226.62-------
Gross Margin62.84-------
Operating Margin-931.23-------
Net Margin-911.85-------
Shares Outstanding72.2971.9671.7371.2763.8963.8263.7763.56
Market Capitalization2,171.133,080.202,870.643,548.151,854.721,502.521,531.232,677.93

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments714.59640.85160.72114.6579.6753.703.19
Short Term Receivables3.293.770.000.000.000.050.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets5.944.344.832.562.540.510.37
Total Current Assets723.81648.97165.54117.2182.2254.263.56
Net Property, Plant & Equipment3.304.333.045.220.000.001.39
Total Investments and Advances0.000.000.010.351.160.290.36
Intangible Assets-----0.00-
Deferred Tax Assets0.570.79-----
Other Assets7.622.386.958.650.370.000.06
Total Assets735.30656.47175.55131.4483.7554.555.38
Short Term Debt Incl. Current Port. of LT Debt0.551.482.442.650.000.000.12
Accounts Payable21.907.6711.1211.991.390.910.34
Other Current Liabilities31.0116.228.7510.966.301.500.60
Total Current Liabilities53.4525.3722.3025.607.692.411.06
Long Term Debt76.7653.1651.2728.644.920.000.01
Provision for Risks Charges0.000.000.000.001.261.630.00
Deferred Tax Liabilities0.570.79-----
Other Liabilities0.000.000.290.290.290.290.76
Total Liabilities130.7879.3273.8654.5314.164.331.83
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00139.5840.09
Common Equity604.52577.15101.6976.9169.59-89.35-36.55
Total Shareholders Equity604.52577.15101.6976.9169.5950.233.55
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity604.52577.15101.6976.9169.5950.233.55
Total Liabilities & Stockholders Equity735.30656.47175.55131.4483.7554.555.38
Book Value Per Share8.489.082.292.773.27-4.20-9.79
Tangible Book Value Per Share8.489.082.292.773.27-4.20-9.79
Full-Time Employees24911251463729-
Price to Book Ratio6.528.055.525.058.176.30-
Return on Assets-43.05-36.57-62.54-82.77-47.16-178.24-
Return on Equity-50.71-44.83-107.50-121.58-54.43-198.65-
Return on Invested Capital-43.98-24.14-62.76-84.37-43.76-106.34-333.26
Quick Ratio13.5425.587.424.5810.6922.553.36
Current Ratio13.5425.587.424.5810.6922.553.36

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-415.31-299.62-152.15-95.99-89.06-32.61-53.41-11.85
Depreciation0.250.472.17-4.09-0.850.180.250.51
Other Funds (Non Cash)70.6935.0512.6413.7615.565.2118.230.54
Funds from Operations-344.37-264.10-137.34-86.31-74.34-27.22-34.93-10.80
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-31.5522.992.66-5.876.753.510.120.52
Cash from Operating Activities-375.92-241.10-134.68-92.18-67.60-23.71-34.81-10.29
Capital Expenditures-0.80-0.63-0.97-0.06-0.060.00-0.10-0.12
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.800.060.00
Purchase or Sale of Investments113.42195.72-424.06-39.37-70.490.000.000.00
Purchase of Investments-381.62-310.45-703.01-224.93-148.490.000.000.00
Sale Or Maturity of Investments495.04506.16278.96185.5678.000.000.000.00
Other Uses-35.00-0.800.000.000.00-5.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities77.62194.29-425.03-39.43-70.55-4.20-0.04-0.12
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock295.85289.08606.67108.8082.1248.9679.840.05
Repurchase of Common Pref Stock0.000.00-0.010.000.000.000.000.00
Sale of Common Pref Stock295.85289.08606.69108.8082.1248.9679.840.05
Proceedsfrom Stock Options282.10282.10593.27107.7480.0348.4179.610.00
Issuance or Reduction of Debt, Net0.0019.820.0024.7419.824.925.45-0.19
Change in Long Term Debt0.0019.820.0024.7419.824.925.58-0.19
Issuance of Long Term Debt0.0019.820.0024.7419.824.925.600.00
Reduction of Long Term Debt0.000.000.000.000.000.00-0.02-0.19
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities295.85308.90606.67133.54101.9353.8885.29-0.14
Net Change in Cash-2.45262.0846.971.93-36.2225.9750.44-10.55
Free Cash Flow-376.05-241.73-135.65-92.24-67.66-23.71-34.91-10.41
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments384.04499.16596.76714.59497.39556.83
Short Term Receivables14.573.933.913.293.364.20
Inventories7.080.000.000.000.000.00
Other Current Assets9.2611.507.455.945.496.62
Total Current Assets414.95514.59608.12723.81506.23567.65
Net Property, Plant & Equipment0.002.502.753.303.193.62
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets20.500.80----
Deferred Tax Assets---0.57--
Other Assets30.3115.1010.877.628.087.25
Total Assets465.75532.98621.74735.30517.50578.53
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.550.470.85
Accounts Payable20.1714.5713.9121.9017.9513.16
Other Current Liabilities35.6033.7531.2431.0123.4619.54
Total Current Liabilities55.7748.3245.1553.4541.8833.55
Long Term Debt75.4375.2375.0376.7676.7476.70
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.57--
Other Liabilities1.361.681.860.000.000.00
Total Liabilities132.57125.23122.04130.78118.62110.25
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity333.19407.76499.70604.52398.88468.28
Total Shareholders Equity333.19407.76499.70604.52398.88468.28
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity333.19407.76499.70604.52398.88468.28
Total Liabilities & Stockholders Equity465.75532.98621.74735.30517.50578.53
Book Value Per Share4.615.676.978.486.247.34
Tangible Book Value Per Share4.335.666.978.486.247.34
Full-Time Employees362361339249224192
Price to Book Ratio6.526.164.748.113.962.81
Return on Assets-84.48-72.32-59.90-43.05-56.87-44.74
Return on Equity-113.46-91.75-71.32-50.71-73.25-54.83
Return on Invested Capital-22.93-22.67-21.06-13.37-16.88-14.04
Quick Ratio7.3110.6513.4713.5412.0916.92
Current Ratio7.4410.6513.4713.5412.0916.92

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-93.71-109.47-121.03-91.10-80.29-76.53
Depreciation0.950.250.26-1.200.560.56
Other Funds (Non Cash)15.3315.4128.0011.949.147.79
Funds from Operations-77.44-93.81-92.77-80.36-70.59-68.18
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-21.74-6.44-13.7310.368.6913.38
Cash from Operating Activities-99.18-100.25-106.50-69.99-61.91-54.80
Capital Expenditures-0.41-0.11-0.17-0.10-0.13-0.21
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments122.3232.97-122.6480.7769.8928.80
Purchase of Investments-48.51-98.06-210.56-24.50-98.70-97.26
Sale Or Maturity of Investments170.83131.0387.92105.27168.59126.06
Other Uses-20.000.00-15.000.000.00-0.05
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities101.9132.86-137.8280.6669.7628.54
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.711.923.94286.280.800.46
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.711.923.94286.280.800.46
Proceedsfrom Stock Options0.000.000.00282.100.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.0019.82
Change in Long Term Debt0.000.000.000.000.0019.82
Issuance of Long Term Debt0.000.000.000.000.0019.82
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.711.923.94286.280.8020.29
Net Change in Cash6.45-65.47-240.37296.958.65-5.97
Free Cash Flow-99.18-100.25-106.52-70.10-62.04-55.01

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3020.68%12.1M58.7M2.12M
2026-10-1523.22%13.6M58.5M2.15M
2026-09-3029.47%17.2M58.5M2.34M
2026-09-1529.11%17.0M58.5M2.35M
2026-08-3133.99%19.9M58.5M2.07M
2026-08-1428.76%16.8M58.5M1.93M
2026-07-3126.12%15.3M58.5M1.70M
2026-07-1525.78%15.1M58.5M1.58M
2026-06-3023.12%13.5M58.5M1.33M
2026-06-1520.26%11.8M58.4M1.15M
2026-05-2918.54%10.8M58.4M1.18M
2026-05-1517.24%10.1M58.4M1.18M
2026-04-3016.17%9.4M58.0M1.18M
2026-04-1517.15%9.9M57.6M1.19M
2026-03-3116.99%9.8M57.5M1.14M
2026-03-1314.36%8.3M57.5M1.16M
2026-02-2713.29%7.6M57.5M1.30M
2026-02-1314.24%8.0M56.4M1.36M
2026-01-3014.27%8.1M56.7M1.54M
2026-01-1514.68%8.0M54.8M1.54M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call17.5010.5015.4012.365.0055.000.000.930-0.1040.006
call20.008.0012.800.004.0740.000.000.914-0.0980.007
call22.505.8010.300.003.3350.000.000.892-0.0910.009
call25.003.206.906.142.03524238.000.858-0.0820.011
call30.000.602.151.501.0061781.000.575-0.1010.019
call35.000.000.500.400.9814,34628.000.205-0.0750.013
call40.000.000.100.041.0654666.000.051-0.0300.005
call45.000.000.950.051.35719.000.000.041-0.0320.004
call50.000.000.400.051.6415860.000.035-0.0340.004
call55.000.004.900.451.8890.000.000.032-0.0360.003
put17.500.001.000.002.8410.000.00-0.070-0.1020.006
put20.000.001.150.252.28654.000.00-0.086-0.0960.007
put22.500.001.150.001.7860.000.00-0.108-0.0890.009
put25.000.000.500.181.32230.000.00-0.142-0.0790.011
put30.000.751.451.100.9031023.00-0.425-0.0980.019
put35.002.807.205.782.2872.000.00-0.795-0.0720.013
put40.007.4012.000.002.8440.000.00-0.948-0.0250.005
put45.0012.3017.000.003.3640.000.00-0.959-0.0270.004
put50.0017.4022.000.003.7950.000.00-0.965-0.0290.004
put55.0022.3027.000.004.1640.000.00-0.968-0.0300.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-124/A2026-07-07SEC
2026-08-124/A2026-06-23SEC
2026-08-124/A2026-05-12SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-07SCHEDULE 13GSEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-053Initial statement of beneficial ownership of securities2026-08-03SEC
2026-07-30SCHEDULE 13G/ASEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-098-KCurrent report2026-07-09SEC
2026-07-078-KCurrent report2026-07-07SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-028-KCurrent report2026-06-02SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC
2026-05-264Statement of changes in beneficial ownership of securities2026-05-21SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09001.33M2
2026-080000
2026-07001.96M1
2026-0600701.77K1
2026-0500679.75K1
2026-04001.01M1
2026-030000
2026-02001.41M7
2026-010000
2025-12249.99K11.35M3
2025-1100543.37K2

Institutional holders

Manager% owned
BlackRock, Inc.8.01%
Avoro Capital Advisors LLC7.97%
STATE STREET CORP5.78%
PRICE T ROWE ASSOCIATES INC /MD/5.59%
Deep Track Capital, LP5.57%
DEERFIELD MANAGEMENT COMPANY, L.P.5.46%
Kynam Capital Management, LP4.03%
MORGAN STANLEY3.90%
Sofinnova Investments, Inc.3.89%
FMR LLC3.87%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.69%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.69%
iShares Russell 2000 ETF2.32%
T. Rowe Price New Horizons Fund, Inc.1.41%
Fidelity Growth Company Fund1.21%
T. Rowe Price Health Sciences Fund, Inc.1.09%
VANGUARD EXTENDED MARKET INDEX FUND1.06%
Fidelity Small Cap Index Fund0.97%
Small Cap Growth Fund0.92%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund0.90%

OakChart. VERA. Cached 15 minutes.